Summary
Calendly has 2 registry-verified rows in the CertReports index, last verified 17 Sep 2026. The strongest row is CSA STAR: STAR Level 1 self-assessment (CAIQ). This page is independent of the vendor’s own trust centre: dates, sources and caveats come from CertReports captures.
Reviewer brief
As of 17 Sep 2026, Calendly is listed in the CSA STAR registry with a STAR Level 1 self-assessment (CAIQ) issued 19 Aug 2022, with no expiry date provided. As of 17 Sep 2026, Calendly is listed in the EU-US Data Privacy Framework registry with an active status covering EU-US Certification, UK Extension Certification, and SW-US Certification, issued 06 Sep 2023 and expiring 21 Oct 2026. As of 17 Sep 2026, no public evidence found for SOC 2 for Calendly. As of 17 Sep 2026, no public evidence found for HIPAA or a BAA offering for Calendly. As of 17 Sep 2026, no subprocessor list evidence was found for Calendly, with zero entries recorded.
- CSA STAR: listed in CSA STAR registry, STAR Level 1 self-assessment (CAIQ), issued 19 Aug 2022, no expiry date (as of 17 Sep 2026).
- EU-US Data Privacy Framework: listed in DPF registry, active (EU-US, UK Extension, SW-US Certifications), issued 06 Sep 2023, expires 21 Oct 2026 (as of 17 Sep 2026).
- SOC 2 and HIPAA: no public evidence found for Calendly (as of 17 Sep 2026).
Facts only, each dated; nothing here is inferred, scored or advised. Brief generated 17 Sep 2026; it is regenerated whenever a row changes.
Among scheduling vendors
2verified rows
Category median 0.5, across 8 indexed scheduling vendors. Calendly has more verified rows than 100 percent of them.
availability managementcalendar managementmeeting automationscheduling
Compare with similar vendors
Pick your own comparisonCompliance grid
Legal artefacts
No DPA, BAA or subprocessor list has been captured from a public page yet. Registry rows above do not depend on this.
Subprocessors
No subprocessor list captured yet.
Similar vendors with evidence
Related by product tags and the Scheduling category, ranked by shared tags, description similarity and overlapping evidence. Never by popularity.
